Communiqués Lumosa Therapeutics Co., Ltd.

Actions

6535

TW0006535008

Cours en clôture Taipei Exchange Autres places de cotation 00:00:00 04/06/2024			Varia. 5j.	Varia. 1 janv.
181 ^TWD	0,00%		-6,70%	+165,01%

14/05	Lumosa Therapeutics Co. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
14/05	Lumosa Therapeutics Co. annonce le changement de son président	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lumosa Therapeutics : Board Approved the Revised Exclusive Licensing Agreement for the Veterinary Analgesic	09/08/22	PU
Lumosa Therapeutics : Board Approved the Binding Term Sheet for LT1001, a Long-acting Analgesic Injection, with a Pakistani Pharmaceutical Company	09/08/22	PU
Lumosa Therapeutics : Board of Directors approved the Cancellation of Restricted Shares to Employees Stock Awards	09/08/22	PU
Lumosa Therapeutics : Board of Directors approved the consolidated financial report for the second quarter of 2022	09/08/22	PU
Lumosa Therapeutics : Partner, AMed Co., Informed the Receipt of Market Authorization from Malaysia NPRA for Naldebain, an Extended-Release Analgesic Injection	05/06/22	PU
Lumosa Therapeutics : Board Approved the Amendments for the Exclusive Licensing Agreement for the Veterinary Analgesic	31/05/22	PU
Lumosa Therapeutics : Shareholders' Meeting approved to release the company's directors from non-competition restrictions	24/05/22	PU
Lumosa Therapeutics : Important resolutions of LUMOSA's 2022 Annual Shareholders' Meeting	24/05/22	PU
Lumosa Therapeutics : Announcement of cancellation of part of new restricted employee shares by relevant authority	20/05/22	PU
Lumosa Therapeutics : Board of Directors not to proceed with the private placement of ordinary shares approved by the 2021 annual general meeting of shareholders	22/04/22	PU
Lumosa Therapeutics : Board of Directors approved the Cancellation of Restricted Shares to Employees Stock Awards	22/04/22	PU
LUMOSA Therapeutics : announces TFDA’s clearance of Phase 2 IND application for multiple-dose of LT3001 in patients with acute ischemic stroke.	24/03/22	PU
Lumosa Therapeutics : Board of Directors approved the convening of the 2022 Annual shareholders' Meeting	04/03/22	PU
Lumosa Therapeutics : Board of Directors approved to issue common shares via private placement.	04/03/22	PU
Lumosa Therapeutics : Board of Directors approved the 2021 consolidated financial report	04/03/22	PU
Lumosa Therapeutics : Receives the Results of LT1001 Phase 3 Trial Conducted by Chinese Partner, Jemincare	25/02/22	PU
Lumosa Therapeutics : Announcement of cancellation of part of new restricted employee shares by relevant authority	23/02/22	PU
Lumosa Therapeutics : Announces US FDA Clearance of IND Application for a Phase 2 Multi-Dose Study of LT3001 in Patients with Acute Ischemic Stroke.	09/02/22	PU
Lumosa Therapeutics : Announces the Termination of “Comparative BA Study” for Naldebain, a New Long-Acting Analgesic Injection, in the US Due to Additional USFDA Requirements	26/01/22	PU
Lumosa Therapeutics : Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke	03/08/21	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Lumosa Therapeutics Co., Ltd.

Actions

6535

TW0006535008

Communiqués

Filtres